About this Journal Submit a Manuscript Table of Contents

Oxidants and Antioxidants in Metabolic Syndrome and Cancer

Call for Papers

Metabolism-related research has become one of the most active areas in the biomedical field. In medicine, metabolism-related diseases are the most relevant to metabolic syndrome, which includes at least atherosclerosis-based ischemic cardio- or cerebral-vascular diseases, hypertension, dyslipidemia, obesity, and diabetes. In recent years, similar metabolic changes were also observed in tumors, putting forward the trend that tumors should also be treated as metabolic diseases. Meanwhile, in the past decade, a growing body of evidence has implicated that increased oxidative stress is a common and key feature of metabolic diseases. But how the active oxidants are generated and regulated during the initiation or development of metabolic syndrome and cancer is far from being fully elucidated. On the other side, how the classical drugs currently in use and the prospective new drugs under R 8 D are able to regulate the oxidative homeostasis also remains largely unknown. Therefore, further investigation into these subjects will help clarify the critical roles of reactive oxygen species (ROS) in these disease states and thereby validate the proper use of antioxidants in the prevention or treatment of metabolic disorders.

We invite authors to submit original research and review articles that seek to define the understanding of the pathophysiology of oxidants or pharmacology of antioxidants in metabolic syndrome or cancer. Potential topics include, but are not limited to:

  • The roles of ROS by different origins, including mitochondria, NADPH oxidases, and other enzyme or non-enzyme-mediated pathways
  • Regulation of ROS homeostasis in metabolic syndrome or cancer
  • How do oxidants regulate metabolism and how does altered metabolism affect the oxidative stress in the development of diseases?
  • How do antioxidants exert beneficial effects to metabolic diseases and what are the potential risks?
  • Advances in the above fields

Before submission, authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/omcl/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/omcl/antim/ according to the following timetable:

Manuscript DueFriday, 14 February 2014
First Round of ReviewsFriday, 9 May 2014
Publication DateFriday, 4 July 2014

Lead Guest Editor

  • Si Jin, Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China

Guest Editors

  • Yongzhong Wu, Laboratory of Molecular Pharmacology, Oxidative Signaling and Molecular Therapeutics Section, National Cancer Institute, Bethesda, MD, USA
  • Shiwei Deng, Department of Pharmacology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
  • Jinxiang Zhang, Department of Surgery, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Hubei, China
  • Xiaoqian Chen, Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China